Free Trial
ETR:BIO

Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis

Biotest Aktiengesellschaft logo

About Biotest Aktiengesellschaft Stock (ETR:BIO)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
€40.80
€41.80
52-Week Range
N/A
Volume
350 shs
Average Volume
1,927 shs
Market Capitalization
$807.43 million
P/E Ratio
9.83
Dividend Yield
0.10%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Remove Ads
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
Biotest Aktiengesellschaft (BIO.DE)
Biotest Aktiengesellschaft (BIESF)
Biotest Aktiengesellschaft (BIO3.F)
Biotest Aktiengesellschaft (BIO3.SW)
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Biotechnology
Sub-Industry
Measuring And Control Equipment
Current Symbol
ETR:BIO
CIK
N/A
Fax
N/A
Employees
8,200
Year Founded
N/A

Profitability

Trailing P/E Ratio
9.83
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$164.40 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$781.30 million
Price / Cash Flow
31.04
Book Value
€14.18 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$807.43 million
Optionable
Not Optionable
Beta
0.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (ETR:BIO) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners